Data collection for the sake of data collection 175 8♦ 42. Miller JE, Ross JS, Moch KI, Caplan AL. Characterizing expanded access and compassionate use programs for experimental drugs. BMC Res Notes. 2017;10(1):350. doi:10.1186/s13104-017-2687-5 43. McKee AE, Markon AO, Chan-Tack KM, Lurie P. How Often Are Drugs Made Available Under the Food and Drug Administration’s Expanded Access Process Approved? J Clin Pharmacol. 2017;57:S136-S142. doi:10.1002/jcph.960 44. The National Institute for Health and Care. Guide to the methods of technology appraisal. Nice. 2018;(April 2013):1-93. 45. Bell H, Wailoo AJ, Hernandez M, et al. The use of real world data for the estimation of treatment effects in NICE decision making. 2016;2016(June):1-61. 46. Faria R, Hernández Alava M, Manca A, Wailoo AJ. The use of observational data to inform estimates of treatment effectiveness in technology appraisal: Methods for comparative individual patient data. NICE Decis Support Unit. 2015;(0):0-85. 47. National Institute for Health and Clinical Excellence (NICE). Guide to the Single Technology Appraisal Process.; 2009. 48. National Institute for Health and Clinical Excellence (NICE). Guide to the Multiple Technology Appraisal Process.; 2009. 49. Dias S, Welton NJ, Sutton AJ, Ades AE. Evidence synthesis for decision making 1: Introduction. Med Decis Making. 2013;33(5):597-606. doi:10.1177/0272989X13487604 50. Polak TB, van Rosmalen J, Uyl - de Groot CA. Expanded access as a source of real-world data: An overview of FDA and EMA approvals. Br J Clin Pharmacol. Published online March 22, 2020. doi:10.1111/bcp.14284 51. Polak TB, van Rosmalen J, Uyl - de Groot CA. Response to Open Peer Commentary “ Making It Count : Extracting Real World Data from Compassionate Use and Expanded Access Programs ” Response to Open Peer Commentary “ Making It Count : Extracting Real World Data from Compassionate Use and Expanded Acces. Am J Bioeth. 2020;20(11):W4-W5. doi:10.1080/1 5265161.2020.1820113 52. Rozenberg O, Greenbaum D. Making It Count: Extracting Real World Data from Compassionate Use and Expanded Access Programs. Am J Bioeth AJOB. 2020;20(7):89-92. doi:10.1080/15 265161.2020.1779857 53. Kang S, Chang S, Ross JS, Miller JE. Implementation of 21st Century Cures Act Expanded Access Policies Requirements. Clin Pharmacol Ther. Published online September 2021. doi:10.1002/cpt.2401 54. Polak TB, Bunnik EM. Financial considerations in expanded access policy for gene therapies: A tough nut to crack? Mol Ther. 2021;29(6):20212021. doi:10.1016/j.ymthe.2021.04.030 55. Taylor DJ, Hobby AE, Binns AM, Crabb DP. How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review. BMJ Open. 2016;6(12):e011504-e011504. doi:10.1136/ bmjopen-2016-011504 56. Chandra A, Lewis EF, Claggett BL, et al. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGMHF Trial. JAMA Cardiol. 2018;3(6):498-505. doi:10.1001/jamacardio.2018.0398 57. Polak TB, Cucchi DGJ, van Rosmalen J. [Expanded Access in The Netherlands: prescribing unregistered medicine]. Ned Tijdschr Geneeskd. 2021;165:1-5. 58. Bunnik EM, Aarts N. What do patients with unmet medical needs want? A qualitative study of patients’ views and experiences with expanded access to unapproved, investigational treatments in the Netherlands. BMC Med Ethics. 2019;20(1):80-80. doi:10.1186/s12910-0190420-8 59. National Institute for Health and Care Excellence. Single technology appraisal: User guide for company evidence submission. 2018;(January 2015):1-36. 60. Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, et al. Differences in Trial and Realworld Populations in the Dutch Castrationresistant Prostate Cancer Registry. Eur Urol Focus. 2018;4(5):694-701. doi:10.1016/j. euf.2016.09.008
RkJQdWJsaXNoZXIy MTk4NDMw